Update on clinical antifungal susceptibility testing for Candida species

Pharmacotherapy

Volumn 18, Issue 3, 1998, Pages 509-515

  Lewis, Russell E ^a   Klepser, Michael E ^a   Pfaller, Michael A ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

CANDIDA; CANDIDIASIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG SENSITIVITY; FUNGUS MUTATION; HOSPITAL INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; REVIEW;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; UNITED STATES;

EID: 0031970846     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Wey S, Mori M, Pfaller M, et al. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-5.
2. Beck-Saugue C, Jarvis W. Secular trends in nosocomial primary blood stream infections in the United States 1980-1990. J Infect Dis 1993;167:1247-51.
3. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in primary nosocomial primary blood stream infections in the United States 1980-1989. Am J Med 1991;91(suppl 3B):86S-9.
4. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiological laboratory. Clin Microbiol Rev 1993;6:428-42.
5. Jones RN, Marshall SA, Pfaller MA, et al. Nosocomial enterococcal blood stream infections in the SCOPE program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. Diagn Microbiol Infect Dis 1997;29:95-102.
6. Miller PJ, Wenzel RP, Etiologic organisms as independent predictors of of death and morbidity associated with blood stream infections. J Infect Dis 1987;156:471-7.
7. Pfaller MA. Epidemiology and control of fungal infections. Clin Infect Dis 1994;19:(suppl 1):S8-13.
8. Jarvis WR. Epidemiology of nosocomial fungal infections with an emphasis on Candida species. Clin Infect Dis 1995;20:1526-30.
9. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996;22(suppl 2):S89-94.
10. Wingard JR. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993;37:1847-9.
11. Price MF, Larocco MT, Gentry LD. Fluconazole susceptibility of Candida species and distribution of species recovered from blood cultures over a five year period. Antimicrob Agents Chemother 1994;38:1422-4.
12. Blinkhorn RJ, Adelstein D, Spagnuolo PJ. Emergence of a new opportunistic pathogen, Candida lusitaniae. J Clin Microbiol 1989;27:236-40.
13. Sanchez V, Vasquez JA, Barth-Jones D, et al. Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. Am J Med 1993;94;577-82.
14. Nguyen MH, Peacock JE, Morris AJ, et al. The changing face of Candidemia: emergence of non-Candida albicans species and antifungal resistance Am J Med 1996;100:617-23.
15. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995;20:15-25.
16. Aisner J, Schimpf SC, Sutherland JC, et al. Turolopsis glabrata infections in patients with cancer: increasing incidence and relationship to colonization. Am J Med 1976;61:23-8.
17. Goldman M, Pottage JC, Weaver DC. Candida krusei fungemia: report of 4 cases and a review of the literature. Medicine 1993;72:143-50.
18. Akova M, Akalin HE, Uzen Ö, Gür D. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole [letter]. Eur J Clin Microbiol Infect Dis 1991;10:598-9.
19. Rex JH, Pfaller MA, Barry AL, et al. Antifungal susceptibility testing of isolates from a randomized multicenter trial of fluconazole verses amphotericin B as treatmeni of non-neutropenic patients with candidemia. Antimicrob Agents Chemother 1995;39:40-4.
20. Pfaller MA, Rex JH, Rinaldi MG. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis 1997;24:776-84.
21. Demuri GP, Hosteller MK, Resistance to antifungal agenls. Pediatr Clin North Am 1995;42:665-85.
22. Chauvanet P, Lopez J, Grappin M. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vilro-in vivo correlation in HIV-infected patients. AIDS 1994;8:945-50.
23. Maenza JR, Merz WG, Romangnoli MJ. Infection due to fluconazole resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997;24:28-34.
24. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vivo-in vitro correlation data for fluconazole, itraconazole and Candida infections. Clin Infect Dis 1997,24:235-47.
25. Powderly WG, Kobyashi GS, Herzig GP, et al. Amphotericin B resistant yeast infection in severely immunocorapromised patients. Am J Med 1988;84:826-32.
26. Wingard J, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-7.
27. Weems JJ. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis 1992;14:756-66.
28. Hadfield TL, Smith MB, Winn RE, et al. Mycosis caused by Candida lusitaniae. Rev Infect Dis 1987;9:1006-12.
29. Millon L, Manteaux A, Roboux G, et al. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype J Clin Microbiol 1994;32:1115-18.
30. Newman SL, Flanigan TP, Fisher A. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis 1994;19:684-6.
31. Redding S, Smith J, Farnacci G, et al. Resistance of Candida albicans to fluconazole during the treatment of oropharyngeal candidiasis in a patient with AIDS. Clin Infect Dis 1994;19:684-6.
32. Chryssanthou E, Torssander J, Petrini B. Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients. Scand J Infect Dis 1995;27: 391-5.
33. Pfaller MA, Rhine-Chalberg J, Redding SW, et al. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol 1994;32:59-64.
34. Quereda C, Polanco AM, Giner C, et al. Correlation between in vitro resistance to fluconazole and clinical outcome in oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1996;15:30-7.
35. Ruhnke M, Eigler A, Tennasenn I. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidiasis and human immunodeficiency syndrome. J Clin Microbiol 1994;32:2092-8.
36. Le Guennec R, Reynes J, Michéle M, et al. Fluconazole-and itraconazole-resistant Candida albicans strains from AIDS patients: multilocus enzyme electrophoresis analysis and antifungal susceptibilities. J Clin Microbiol 1995;33:2732-7.
37. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 1997;41:1482-7.
38. White TC. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14 a demethylase in Candida albicans. Antimicrob Agents Chemother 1997;41:1488-94.
39. Dick JD, Merz WG, Saral R. Polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 1979;16:123-6.
40. Notario V, Gale EF, Kerridge D, Wayman F. Phenotypic resistance to amphotericin B in Candida albicans: relationship to glucan metabolism. J Gen Microbiol 1982;128:761-7.
41. Safe LM, Safe SH, Subden RE, Morris DC. Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis. Can J Microbiol 1997;23:398-401.
42. Sokol-Anderson M, Sligh JE, Elberg S, et al. Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B. Antimicrob Agents Chemother 1988;32:702-5.
43. Vanden Bossche H, Marichal P, Odds F. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 1992;36:2602-10.
44. Wheat J, Marichale P, Vanden Bossche H, et al. Hypothesis on the mechanism of resistance of fluconazole in Histoplasma capsulatum. Antimicrob Agents Chemother 1997;41:410-14.
45. Howell SA, Mallet AI, Noble WC. A comparison of the sterol content of multiple isolates of the Candida albicans Darlington strain with other clinically azole-sensitive and -resistant strains. J Appl Bacteriol 1990;69:692-6.
46. Hitchcock CA, Barrett-Bee KJ, Russell NJ. The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans. J Gen Microbiol 1986;132:2421-31.
47. Hitchcock CA, Pye GW, Troke PF. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother 1993;37: 1962-5.
48. Venkateswarlu K, Denning DW, Manning NJ, Kelly SL. Reduced accumulation of drug in Candida krusei. Antimicrob Agents Chemother 1996;40:2443-6.
49. Albertson GD, Masakuzu N, Cannon RD. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 1996;40:2835-41.
50. Parkinson T, Falconer DJ, Hitchcock CA. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob Agents Chemother 1995;39:1696-9.
51. Sanglard D, Kuchler K, Ischer F, et al. Mechanism of resistance to azole antifungals in Candida albicans isolates from AIDS patients involves specific multidrug transporters. Antimicrob Agents Chemother 1995;39:2378-86.
52. r gene. Antimicrob Agents Chemother 1995;39:422-6.
53. Warren NG, Hazen KC. Candida, cryptococcus and other yeasts of medical importance. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. Washington, DC: ASM Press, 1995:697-738.
54. Calhoun DL, Roberts GD, Washkin H, et al. Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing flucytosine and amphotericin. Br J Clin Microbiol 1986;23: 298-301.
55. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. Wayne, PA: Author, 1997.
56. Pfaller MA, Bale M, Buschelman B, et al. Quality control guidelines for the National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol 1995;33:1104-7.
57. Rex JH, Pfaller MA, Lancaster M, et al. Quality control guidelines for National Committee for Clinical Laboratory Standards-recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol 1996;34: 816-17.
58. Rex JH, Pfaller MA, Rinaldi MG, et al. Antifungal susceptibility testing. Clin Microbiol Rev 1993;6:367-81.
59. Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA. Antifungal pharmacodyriamic characteristics of fluconazole and amphotericin B against Candida albicans. Antimicrob Agents Chemother 1997;41:1392-5.
60. Klepser ME, Wolfe EJ, Pfaller MA. Antifungal dynamics of fluconazole and amphotericin B against Cryptococcus neoformans. J Antimicrob Chemother In press.
61. Pfizer-Roerig Inc. Diflucan (fluconazole) package insert. Groton, CT; 1996.
62. Janssen Inc. Sporonox (itraconazole) oral solution package insert. Piscataway, NJ;1997.
63. Goa KL, Barradell LB. Fluconazole. Drugs 1995;56:658-90.
64. Grant SM, Clissold SP. Fluconazole: review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycosis. Drugs 1990;39:877-916.
65. Nguyen MH, Clancy CJ, Yu VL, et al. Do in vitro susceptibility data predict microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998;177:425-30.
66. Kerridge D, Fasoli M, Wayma F. Drug resistance in Candida albicans and Candida glabrata. Ann NY Acad Sci 1988;544:245-57.
67. Espinel-Ingroff A. Etest for antifungal susceptibility testing of yeasts. Diagn Microbiol Infect Dis 1994;19:217-22.